The aim of the study was to study the involvement of monocyte chemoattractant protein-1 in the development of the pathological process in rats with induced chronic colitis and to assess the effectiveness of correcting this condition with cerium dioxide nanoparticles. In rats with chronic colitis, the content of monocyte-chemokine protein-1 increased, compared with the determined indicators of the intact group. This may indicate the involvement of the studied cytokine in the development of the pathological process in the intestines of experimental animals. After the therapy with cerium dioxide nanoparticles, a decrease in the content of monocyte-chemoattractant protein in the blood serum was observed compared to the indicator obtained before the correction, however, this indicator did not return to the values in the control group.

Keywords: experimental colitis, chemokines, cerium dioxide nanoparticles, monocyte chemoattractant protein-1

Full text: PDF (Ukr)

1. Saez A, Herrero-Fernandez B, Gomez-Bris R, Sánchez-Martinez H, Gonzalez-Granado JM.Pathophysiology of inflammatory bowel disease: Innate immune system. Int. J. Mol. Sci.2023;24:1526.doi.org/10.3390/ijms24021526
2. Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease.United Eur. Gastroenterol. J. 2022;10:1047-53.doi.org/10.1002/ueg2.12319
3. Khoon L, Piran R. A New Strategy in Modulating the Protease-Activated Receptor 2(Par2) in Autoimmune Diseases. International Journal of Molecular Sciences. 2025; 26(1):410.doi.org/10.3390/ijms26010410
4. Kim Y, Lee Y, Heo G, Jeong S, Park S, Yoo JW, Jung Y, Im E. Modulation of Intestinal Epithelial Permeability via Protease-Activated Receptor-2-Induced Autophagy. Cells. 2022;11:87.doi.org/10.3390/cells11050878
5. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606-19.doi.org/10.1016/S0140-6736(12)60150-0
6. Yuan S-N, Wang MX, Han JL, Feng CY, Wang M, Wang M, Sun JY, Li NY, Simal-Gandara J, Liu C. Improved colonic inflammation by nervonic acid via inhibition of NF-κB signaling pathway of DSS-induced colitis mice. Phytomedicine. 2023;112:154702.doi.org/10.1016/j.phymed.2023.154702
7. Yi M, Li T, Niu M, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Sig Transduct Target Ther. 2024;9:176.doi.org/10.1038/s41392-024-01868-3
8. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014; 104:15.25.1-15.25.14.doi.org/10.1002/0471142735.im1525s104
9. Guan G, Lan S. Implications of antioxidant systems in inflammatory bowel disease.BioMed Res Int 2018;1-7.doi.org/10.1155/2018/1290179
10. Eichele DD, Kharbanda KK. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis.World J Gastroenterol. 2017;23(33):6016-29.doi.org/10.3748/wjg.v23.i33.6016
11. Ott A, Tutdibi E, Goedicke-Fritz S, Schöpe J, Zemlin M, Nourkami-Tutdibi N. Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease. PLoS One. 2023;18(11): e0288147.doi.org/10.1371/journal.pone.0288147
12. Proma MA, Daria S, Nahar Z, Islam SMA, Bhuiyan MA, Islam R. Monocyte chemoattractant protein-1 levels are associated with major depressive disorder. Journal of Basic and Clinical Physiology and Pharmacology. 2022;33 (6):735-41.doi.org/10.1515/jbcpp-2021-0132
13. Aguilera A, Yanez-Mo M, Selgas R, et al. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients.Curr Opin Investig Drugs. 2005;6:262-68.
14. Khoon L, Piran R. A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases. International Journal of Molecular Sciences. 2025;26(1):410.doi.org/10.3390/ijms26010410
15. Berger M, Guiraud L, Dumas A, Sagnat D, Payros G, Rolland C, Vergnolle N, Deraison C, Cenac N, Racaud-Sultan C. Prenatal stress induces changes in PAR2- and M3-dependent regulation of colon primitive cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2022;323:609-26.doi.org/10.1152/ajpgi.00061.2022
16. Morrison NA, Forwood MR. Monocyte Chemotactic Protein-1 (MCP1) Accumulation in Human Osteoclast Precursor Cultures. Life. 2022; 12(6):789.doi.org/10.3390/life12060789
17. She S, Ren L, Chen P, Wang M, Chen D, Wang Y, Chen H. Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease. Front Immunol. 2022;13:812431.doi.org/10.3389/fimmu.2022.812431
18. Mo Z, Liu D, Chen Y, et al. Single-cell transcriptomics reveals the role of MacrophageNave CD4 + T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. J Transl Med. 2022;20:466.doi.org/10.1186/s12967-022-03675-2
19. Bergemalm D, Anderson E, Hultdin J, Repsilber D, Karling P, Halfvarson J, et al. Systemic inflammation in preclinical ulceratieve colitis. Gastroenterology. 2021;161(5):1526-39.doi.org/10.1053/j.gastro.2021.07.026
20. Kensuke H, Masahiro M, Naoki K, et al. Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-assosiated tumourigenesis by blocking the MCP-1/CCR2 pathway. Sci Rep. 2021;11:19943.doi.org/10.1038/s41598-021-99412-8
21. Losada-Barreiro S, Sezgin-Bayindir Z, Paiva-Martins F, Bravo-Diaz C. Biochemistry of antioxidants: mechanisms and pharmaceutical applications. Biomedicines. 2022;10(12):3051.doi.org/10.3390/biomedicines10123051
22. Liu P, Li Y, Wang R, Ren F, Wang X. Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease. Biomedicines. 2022;10(1):85/ doi.org/10.3390/biomedicines10010085